Relationship Between Brain Glutamate Levels and Clinical Outcome in Individuals at Ultra High Risk of Psychosis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Alterations in brain glutamate levels may be associated with psychosis risk, but the relationship to clinical outcome in at-risk individuals is unknown. Glutamate concentration was measured in the left thalamus and anterior cingulate cortex (ACC) using 3-Tesla proton magnetic resonance spectroscopy in 75 participants at ultra high risk (UHR) of psychosis and 56 healthy controls. The severity of attenuated positive symptoms and overall functioning were assessed. Measures were repeated in 51 UHR and 33 Control subjects after a mean of 18 months. UHR subjects were allocated to either remission (no longer meeting UHR criteria) or non-remission (meeting UHR or psychosis criteria) status on follow-up assessment. Thalamic glutamate levels at presentation were lower in the UHR non-remission (N=29) compared with the remission group (N=22) (t(49)=3.03; P=0.004), and were associated with an increase in the severity of total positive symptoms over time (r=−0.33; df=47; P=0.02), most notably abnormal thought content (r=−0.442; df=47; P=0.003). In the UHR group, ACC glutamate levels were lower at follow-up compared with baseline (F(80)=4.28; P=0.04). These findings suggest that measures of brain glutamate function may be useful as predictors of clinical outcome in individuals at high risk of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 2×
“…neurotransmission are thought to play a key role in the pathophysiology of schizophrenia (Goff and Coyle, 2001; Javitt and Zukin, 1991; Olney and Farber, 1995), and this is supported by evidence from post-mortem, neuroimaging and genetic studies (Harrison and Weinberger, 2005; Konradi…”
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483 · cited 4×
“This study was approved by the Joint South London and Maudsley (SLaM) NHS Trust Research Ethics Committee.”
InfluentialSelf-citationPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020 · cited 1×
“Glutamatergic dysfunction could thus contribute to the loss of grey matter and dopamine dysfunction that are robust features of schizophrenia (Carlsson et al , 2001; Javitt, 2007; Olney et al , 1999).”
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010 · cited 1×
“However, it is likely that glutamatergic transmission in other regions, such as the hippocampus (Kraguljac et al , 2013; Lisman et al , 2008), and striatum (de la Fuente-Sandoval et al , 2013a; de la Fuente-Sandoval et al , 2011) is also important.”
Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Dopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [ 18 F]-DOPA PET Imaging Study
Howes, O. D., Bose, S. K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L. R., Murray, R. M., & McGuire, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010160 · Cited by 343
Self-citationMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · cited 2×
“Abnormalities in glutamatergic neurotransmission are thought to have a key role in the pathophysiology of schizophrenia (Goff and Coyle, 2001; Javitt and Zukin, 1991; Olney and Farber, 1995), and this is supported by evidence from postmortem, neuroimaging, and genetic studies (Harrison and Weinberger, 2005; Konradi an…”
Cited by
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
“These neuro- and social-cognitive abnormalities are also accompanied by various abnormalities in functional and structural imaging [11,52,107], electrophysiological measures [10,85,118], and neurochemistry [19,33,55].”
BackgroundMerritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Translating the MAM model of psychosis to humans
Modinos, G., Allen, P., Grace, A. A., & McGuire, P. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.005 · Cited by 165
“Longitudinal MRS studies could help to resolve this issue, but there are few such studies in the literature [61, 97].”
BackgroundSelf-citationBossong, M. G., Antoniades, M., Azis, M., Samson, C., Quinn, B., Bonoldi, I., Modinos, G., Perez, J., Howes, O. D., Stone, J. M., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3252 · Cited by 81
Self-citationHaarsma, J., Knolle, F., Griffin, J. D., Taverne, H., Mada, M., Goodyer, I. M., The NSPN Consortium, Fletcher, P. C., & Murray, G. K. (2020) · Journal of Abnormal Psychology · doi:10.1037/abn0000494 · Cited by 60
Predicting Remission in Subjects at Clinical High Risk for Psychosis Using Mismatch Negativity
Kim, M., Lee, T. H., Yoon, Y. B., Lee, T. Y., & Kwon, J. S. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx102 · Cited by 45
Metadata
- Authors
- Egerton, A., Stone, J. M., Chaddock, C. A., Barker, G. J., Bonoldi, I., Howard, R. M., Merritt, K., Allen, P., Howes, O. D., Murray, R. M., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., & McGuire, P. K.
- Venue
- Neuropsychopharmacology
- Published
- 2014-06-11
- Volume
- 39
- Issue
- 12
- Pages
- 2891-2899
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2037900657
- Cited by
- 85
- References
- 18
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.